Albireo Pharma

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Albireo’s mission is to bring life-changing treatments to people living with rare diseases.

Albireo’s vision is to become the leader in the discovery and development of bile acid modulators for rare diseases through innovative science and customer-focused collaborations.

The company has won several awards for its commitment to innovation, including the Parenteral Drug Association’s Innovation Award, the Scrip Awards, and the Entrepreneur of the Year award.